Inventaire - dine venner og fællesskaber er dit bedste bibliotek

Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy

forfatter

Elodie A Pérès

1985 -

Samuel Valable

1978 -

Myriam Bernaudin

Eric T MacKenzie

udgivet i: Neuro-Oncology

dato for udgivelse: 2012-10-31

main subject: bevacizumab, temozolomide, glioblastoma multiforme

Cites articles 43

Date

Titel

Forfattere

2012-04-04

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

Marc Sanson, Jean-Yves Delattre, Khe Hoang-Xuan
2012-01-01

Individualized targeted therapy for glioblastoma: fact or fiction?

Michael Weller, Wolfgang Wick, Monika E Hegi, Roger Stupp
2012-03-16

In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology

Benjamin Lemasson
2012-03-20

Neuro-oncology: Glioblastoma--community adjusts to new standard of care.

Henry Seth Friedman, Annick Desjardins
2011-12-01

Response assessment in oncology: limitations of anatomic response criteria in the era of tailored treatments
2011-12-14

[(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells

Carleen Cullinane
2011-12-12

3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab

Timothy F. Cloughesy
2011-04-21

Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model

Franck Sobrio, Samuel Valable, Myriam Bernaudin
2011-07-26

Bevacizumab and daily temozolomide for recurrent glioblastoma

April Coan, Henry Seth Friedman, Annick Desjardins, David A Reardon, James J Vredenburgh, Katherine B Peters, James H. Herndon, Jennifer Marcello, Leighann Bailey
2011-04-29

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

John P. Kirkpatrick, Henry Seth Friedman, Darell D. Bigner, Annick Desjardins, Allan Friedman, David A Reardon, James J Vredenburgh, James H. Herndon, Katherine B Peters, Jennifer Marcello, Leighann Bailey, Stevie Threatt
2011-03-09

Irinotecan and bevacizumab in recurrent glioblastoma multiforme

Ulrik Lassen
2011-02-14

Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer

Laurent Corcos, Catherine Cheze Le Rest, Dimitris Visvikis
2011-02-14

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

Olivier Keunen, Michal Bartos, Radovan Jirik, Simone P Niclou, Rolf Bjerkvig, Morgane Sanzey, Fred Fack, Linda Stuhr, Hrvoje Miletic, Daniel Stieber, Anais Oudin, Torfinn Taxt, Frits Thorsen, Ingrid Moen, Cecilie Brekke Rygh
2011-06-01

Advances in MRI assessment of gliomas and response to anti-VEGF therapy

Jonathan R Young, Benjamin M Ellingson
2011-01-01

The paradoxical effect of bevacizumab in the therapy of malignant gliomas.

Edward Neuwelt
2011-07-25

Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.

Jochen Herms
2011-06-01

O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.

Eugen Trinka
2011-02-17

Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma

Jonathan R Young, Jonathan Goldin, Timothy F. Cloughesy
2010-12-08

Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects
2010-12-06

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

Robert Elashoff, Timothy F. Cloughesy, Albert Lai, Phioanh Nghiemphu, Linda Liau, Whitney Pope, Paul Mischel, Orestes Solis, Michael T Selch, Emese Filka
2010-09-24

Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice

Liselotte Højgaard, Jacob Madsen, Fredrik Björkling, Andreas Kjær
2010-08-10

Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas

Peter Hau
2010-01-01

Pseudoprogression following chemoradiotherapy for glioblastoma multiforme

Arjun Sahgal
2010-02-16

Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers

Thomas L Chenevert
2010-05-01

Noninvasive imaging of endogenous neural stem cell mobilization in vivo using positron emission tomography

Bernd Neumaier, Gereon R. Fink
2009-07-01

Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease
2009-05-01

Pseudoprogression and pseudoresponse: challenges in brain tumor imaging
2009-03-27

NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies
2009-02-27

Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging
2009-01-23

MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model

Jean-Marc Constans, Samuel Valable, Myriam Bernaudin
2009-01-14

Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model

Edward Neuwelt
2009-02-01

Mapping of T1-values and Gadolinium-concentrations in MRI as indicator of disease activity in luminal Crohn's disease: a feasibility study

Aart Nederveen

Artikel - wd:Q36500372

Welcome to Inventaire

dit venne- og fællesskabs bibliotek

vil du vide mere